2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner

BayerThe award-winner of the 2016 Otto Bayer Award has been named: the Board of Trustees of the Bayer Science & Education Foundation and the Scientific Committee for this award have presented Professor Dr. Dirk Trauner with the EUR 75,000 prize, one of Germany's most prestigious scientific accolades. The award is in recognition for his pioneering contributions in "Photopharmacology and Chemical Optogenetics". Trauner developed novel switches that can sensitize a wide variety of cellular processes toward light. His work has potential to open new chemotherapeutical treatment opportunities, including chemical treatment strategies to cure blindness and cancer. The award will be officially presented by Werner Baumann, who will become the CEO of Bayer at May 1, 2016, at a ceremony in Berlin on June 6, 2016.

The Otto Bayer Award honors scientists who have conducted pioneering research in innovative areas of chemistry and biochemistry. It has been presented since 1984 in memory of its endower Professor Dr. Otto Bayer (not related to the company founder). The long-tenured Head of Research at Bayer AG invented polyurethane chemistry. He strengthened the contact of industry and academia and supported the training of young scientist throughout his long career.

Prof. Ernst-Ludwig Winnacker, Chairman of the Board of Trustees of the Bayer Science & Education Foundation, said: "Photopharmacology is the control of small molecules by light. The precision of their effects in biological systems can be increased so fundamental that this concept has become an indispensable tool of modern cell biology research and already provides important impetus for future applications in neuroscience and cancer. Dirk Trauner is a pioneer of this technology at the interface between biology and chemistry, and therefore seems to the jury an ideal candidate for the most prestigious Otto Bayer Award."

The Otto Bayer 2016Award is being given in recognition of this innovative technology, but also on the broad objective of Trauner’s research: to demonstrate the awesome power of chemical synthesis with challenging target molecules and to use it toward the establishment of synthetic biological pathways. This work is of high value for a life science company as Bayer, where a major part of the business is to invent and produce new molecules that interact with the biochemical processes in various living species.

"Our future will be shaped by advances in basic and applied research. We want to promote science and strengthen excellence," said Kemal Malik, member of the Bayer Board of Management for Innovation and Chairman of the foundation. "Research plays a central role for the inventor company Bayer. The knowledge, acceptance and application of future technologies in the life sciences are key framework conditions in our society, and Bayer AG wants to contribute to establishing them among other means through its foundations and by awarding this prize," Malik continued.

The prize is awarded by the Bayer Science & Education Foundation. The foundation acts as initiator, promoter and partner for progress at the interface between industry, academia and civil society. The primary objectives are the recognition of frontier research, the promotion of science talents and the support for innovative school science projects. In terms of content, the activities focus on life science, health and medicine. The foundation honors frontier research achievements every two years with the Otto Bayer Award and in alternate years with the Hansen Family Award, each of which carries prize money of EUR 75,000. In addition, the foundation presents two talent awards: The international Bayer Early Excellence in Science Award in biology, chemistry and medical science, each with prize money of EUR 10,000, and the Bayer Thrombosis Research Award for basic and clinical thrombosis research with prize money of EUR 30,000.

The new Otto Bayer Award winner, Dirk Trauner was born and raised in Linz, Austria, studied biology and chemistry at the University of Vienna, and received his undergraduate degree in chemistry from the Free University, Berlin. He then pursued a PhD in chemistry under the direction of Prof. Johann Mulzer, with whom he moved to the University of Frankfurt and then back to Vienna. Following a mandatory stint in the Austrian Army, he became a postdoctoral fellow with Prof. Samuel J. Danishefsky at the Memorial Sloan-Kettering Cancer Center. After two great years in New York City, Trauner joined the Department of Chemistry at the University of California, Berkeley, where he rose through the ranks to become an Associate Professor of Chemistry (with tenure). He was also appointed as a member of the Lawrence Berkeley National Laboratory. In the summer of 2008, he moved to the University of Munich, where he currently resides as a Professor of Chemical Biology and Chemical Genetics. Despite his extensive forays into biology and physiology Trauner remains an organic chemist at heart, as evidenced by the synthesis of more than 80 natural products.

Dirk Trauner has been awarded the 2016 Emil Fischer Medal and is a Corresponding Member of the Austrian Academy of Sciences and a Fellow of the Royal Society of Chemistry. He is also the recipient of the Kitasato Medal, the Alfred P. Sloan Fellowship, an ERC Advanced Grant, and the Austrian Chemical Society Award for the best thesis in 1997. He sits on the editorial board of Natural Product Reports and the editorial advisory board of ACS Central Science, ACS Chemical Neuroscience, Cell Chemical Biology and Chem.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]